You are here
Chlamydia, gonorrhoea and syphilis IVD self-tests
The purpose of this document is to provide manufacturers and sponsors with guidance on the Therapeutic Goods Administration's (TGA) expectations concerning clinical performance requirements (i.e. clinical sensitivity and specificity) and risk mitigations for in vitro diagnostic medical devices (IVDs) intended to be used as self-tests for Chlamydia trachomatis (chlamydia), Neisseria gonorrhoeae (gonorrhoea) and Treponema pallidum (syphilis).
- Public health context
- Clinical performance characteristics and risk mitigation strategies for IVD self-testing
- Clinical requirements for chlamydia, gonorrhoea and syphilis self-tests
- Usability studies
We aim to provide documents in an accessible format. If you are having problems using a document with your accessibility tools, please contact us for help.